Novel immunotherapy in metastatic renal cell carcinoma

Area of Science:

• Oncology
• Immunology
• Nephrology

Background:

• Metastatic renal cell carcinoma (mRCC) remains a challenging cancer with a poor prognosis.
• Standard treatments include targeted antiangiogenic therapies and traditional immunotherapies like interleukin-2 and interferon-α.

Purpose of the Study:

• To review the current landscape of standard and emerging immune therapeutics for mRCC.
• To highlight promising novel immunotherapy agents and other modalities in development.

Main Methods:

• Literature review of standard and emerging treatments for mRCC.
• Summary of current research on novel immunotherapies such as cancer vaccines, adoptive cell therapy, and checkpoint inhibitors.

Main Results:

• Despite advances, mRCC prognosis remains poor.
• Novel immunotherapies, including programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) pathway inhibitors, are showing promise.
• Emerging agents represent important steps in managing mRCC.

Conclusions:

• Current standard therapies for mRCC have limitations in improving patient outcomes.
• Novel immunotherapies offer significant potential for advancing mRCC treatment.
• Further research into immune-based strategies is crucial for improving mRCC management.